Towa Pharmaceutical Co., Ltd. (TWAPF)

Towa Pharmaceutical Co., Ltd. (TWAPF) — VMCI valuation read

Towa Pharmaceutical Co., Ltd. sits at VMCI 59/100, with the Healthcare sector median at 50. That 9-point spread is the first thing to note on TWAPF: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on TWAPF are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on TWAPF: TWAPF trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 2.5x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

TWAPF rose 1.1% over the trailing 7 days, with a -21.6% read on a 30-day basis.